SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Other EventsItem 9.01Other Events
On October 17, 2017, Spectrum Pharmaceuticals, Inc. (the “Company”) announced the oral presentation of interim data from a Phase 2 clinical study evaluating poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer (NSCLC) by scientists fromthe MD Anderson Cancer Center which was presented inYokohama, Japan,October 15-18, 2017. A copy of this press release announcing the interim data is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 9.01 by reference.
Item 9.01Regulation FD Disclosure
On October 18, 2017, the Company held a conference call at 8:30 a.m. Eastern Time to further discuss the poziotinib study results. Interested parties may access a replay of the webcast, including presentation materials, on the investor relations page of the Company’s website: http://investor.sppirx.com/events.cfm.
The information contained in Item 9.01 of this Current Report on Form 8-K, including without limitation any information contained on the Company’s website, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits
SPECTRUM PHARMACEUTICALS INC ExhibitEX-99.1 2 ex991pressrelease.htm EXHIBIT 99.1 Exhibit COMPANY CONTACTShiv KapoorVice President,…To view the full exhibit click here
About SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI)
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.
